Claims

1. Use of compound A :



Compound A,

in the manufacture of a medicament for the treatment of lung cancer in a human subject in need thereof, wherein a total daily dose of 50 mg to 600 mg of Compound A is to be orally administered to the subject, and wherein the lung cancer comprises a RAS G12C mutation.

2. The use of claim 1, wherein a total daily dose of 100 mg to 600 mg of Compound A is to be orally administered to the subject.

3. The use of claim 1, wherein a total daily dose of 200 mg to 600 mg of Compound A is to be orally administered to the subject.

4. The use of claim 1, wherein a total daily dose of 300 mg to 600 mg of Compound A is to be orally administered to the subject.

5. The use of claim 1, wherein a total daily dose of 400 mg to 600 mg of Compound A is to be orally administered to the subject.

6. The use of any one of claims 1 to 5, wherein a total daily dose of 400 mg of Compound A is to be orally administered to the subject.

7. The use of any one of claims 1 to 6, wherein Compound A is to be administered once daily or twice daily.

8. The use of any one of claims 1 to 3, wherein Compound A is to be orally administered twice-daily to the subject, and each dose comprises 200 mg of Compound A.

9. The use of any one of claims 1 to 6, wherein Compound A is to be orally administered once-daily to the subject at a dose of 400 mg of Compound A.

10. The use of any one of claims 1 to 9, wherein the subject is to be administered Compound A for at least 1 month.

11. The use of any one of claims 1 to 9, wherein Compound A is to be administered in treatment cycles and each treatment cycle is 21 days.

12. The use of any one of claims 1 to 11, wherein the lung cancer is non-small cell lung cancer.

13. The use of any one of claims 1 to 12, wherein the RAS protein is KRAS.

14. The use of any one of claims 1 to 13, wherein an additional therapeutic agent is to be administered.

15. The use of claim 14, wherein the additional therapeutic agent is a RAS(ON) multi-selective inhibitor.

16. The use of claim 14, wherein the additional therapeutic agent is a pan-KRAS inhibitor.

17. The use of claim 15, wherein the pan-KRAS inhibitor is a pan-KRAS(OFF) inhibitor.

18. The use of claim 14, wherein the additional therapeutic agent is a PD-1 and/or PD-L1 inhibitor.

19. The use of claim 14, wherein the additional therapeutic agent is RMC-6236:



.

20. Use of compound A :



Compound A

in the manufacture of a medicament for the treatment of non-small cell lung cancer (NSCLC) comprising a RAS G12C mutation in a human subject in need thereof, wherein a total daily dose of 200 mg to 600 mg of Compound A is to be orally administered to the subject, wherein Compound A is to be administered twice daily.

21. The use of claim 20, wherein the RAS is KRAS.

22. The use of claim 20 or 21, wherein Compound A is to be administered twice daily, and each dose comprise 200 mg Compound A.

23. The use of any one of claims 20 to 22, wherein the subject has received at least one prior cancer therapy.

24. The use of any one of claims 20 to 23, wherein the subject has locally advanced or metastatic NSCLC.

25. The use of any one of claims 20 to 24, wherein the subject has received a prior $KRAS^{G12C}$(OFF) inhibitor.

26. The use of any one of claims 20 to 24, wherein the subject is naïve to a $KRAS^{G12C}$(OFF) inhibitor.

27. The use of any one of claims 1 to 26, wherein the subject has been previously treated with a RAS(OFF) inhibitor and the subject’s cancer progresses on the RAS(OFF) inhibitor.